Immuneering Q2 Net Loss $17.3M; Atebimetinib Phase 3 Trial Underway
Immuneering Corporation reported a net loss of $17.3 million, or $0.27 per share, for the second quarter ended June 30, 2026. The company ended the quarter with $182.7 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2029. Operationally, Immuneering announced that its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line pancreatic cancer is underway, building on compelling Phase 2a data showing 17.3 month median overall survival. Additionally, Andrew Gengos was appointed as the new Chief Financial Officer.
Key Highlights
- Immuneering reported a net loss of $17.3 million for Q2 2026, compared to $14.4 million for Q2 2025.
- Net loss per share was $0.27 for Q2 2026, down from $0.40 per share in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $182.7 million as of June 30, 2026.
- The company anticipates a cash runway into 2029.
- R&D expenses increased to $14.0 million in Q2 2026 from $10.5 million in Q2 2025.
- G&A expenses rose to $5.0 million in Q2 2026 from $4.3 million in Q2 2025.
- The pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line pancreatic cancer is underway.
- Phase 2a data showed 17.3 month median overall survival in pancreatic cancer patients.
Price Impact
More from IMRX
Immuneering Q2 Net Loss Widens to $17.27M; Cash $41.32M
Immuneering Q2 Net Loss $17.3M; Atebimetinib Phase 3 Underway, Positive ASCO Data
Immuneering's Atebimetinib Shows Broad Antitumor Activity in Preclinical Study